Suppr超能文献

用于血管性血友病因子活性测定的自动预稀释装置。

An Automated pre-Dilution Setup for Von Willebrand Factor Activity Assays.

作者信息

Schachinger Tobias, Holik Ann-Katrin, Schrenk Gerald, Gritsch Herbert, Hofbauer Stefan, Furtmüller Paul G, Turecek Peter L

机构信息

Analytical Development Europe, Baxalta Innovations GmbH, a Takeda company, Vienna, Austria.

Institute of Biochemistry, Department of Chemistry, BOKU University, Vienna, Austria.

出版信息

Bio Protoc. 2024 Sep 5;14(17):e5059. doi: 10.21769/BioProtoc.5059.

Abstract

Accurate quantification of von Willebrand factor ristocetin cofactor activity (VWF:RCo) is critical for the diagnosis and classification of von Willebrand disease, the most common hereditary and acquired bleeding disorder in humans. Moreover, it is important to accurately assess the function of von Willebrand factor (VWF) concentrates within the pharmaceutical industry to provide consistent and high-quality biopharmaceuticals. Although the performance of VWF:RCo assay has been improved by using coagulation analyzers, which are specialized devices for blood and blood plasma samples, scientists still report a high degree of intra- and inter-assay variation in clinical laboratories. Moreover, high, manual sample dilutions are required for VWF:RCo determination of VWF concentrates within the pharmaceutical industry, which are a major source for assay imprecision. For the first time, we present a precise and accurate method to determine VWF:RCo, where all critical pipetting and mixing steps are automated. A pre-dilution setup was established on CyBio FeliX (Analytik-Jena) liquid handling system, and an adapted VWF:RCo method on BCS-XP analyzer (Siemens) is used. The automated pre-dilution method was executed on three different, most frequently used coagulation analyzers and compared to manual pre-dilutions performed by an experienced operator. Comparative sample testing revealed a similar assay precision (coefficient of variation = 5.9% automated, 3.1% manual pre-dilution) and no significant differences between the automated approach and manual dilutions of an expert in this method. While no outliers were generated with the automated procedure, the manual pre-dilution resulted in an error rate of 8.3%. Overall, this operator-independent protocol enables standardization and offers an efficient way of fully automating VWF activity assays, while maintaining the precision and accuracy of an expert analyst. Key features • Automated pre-dilution setup for von Willebrand factor concentrates of various natures. • Combination of a liquid handling system (CyBio FeliX) with a coagulation analyzer (BCS-XP). • Simplifies method transfer to other laboratories. • Basic training for CyBio FeliX and BCS-XP is required. Graphical overview Platelets (yellow ellipsoids) with negative surface charge (- - -) are treated with formaldehyde, which partly denatures the cell surface and thus stabilizes platelets for use as assay reagents. Stabilized platelets (dark-yellow-framed yellow ellipsoids) are then brought in contact with ristocetin A (chemical structure shown; black dots), which binds to the platelet surface and facilitates binding of VWF (green circles). The graphs show an example of quantitative determination of platelet agglutination by measurement of light transmission, where increasing amounts of VWF increase light transmission over time. The photo in the left-bottom corner shows the CyBio FeliX setup for VWF sample dilution and the photo in the right-bottom corner displays the BCS-XP system, which is used for VWF:RCo measurements.

摘要

准确量化血管性血友病因子瑞斯托霉素辅因子活性(VWF:RCo)对于血管性血友病(人类最常见的遗传性和获得性出血性疾病)的诊断和分类至关重要。此外,在制药行业中准确评估血管性血友病因子(VWF)浓缩物的功能对于提供一致且高质量的生物制药也很重要。尽管使用凝血分析仪(专门用于血液和血浆样本的设备)已提高了VWF:RCo检测的性能,但科学家们仍报告临床实验室中存在高度的批内和批间差异。此外,制药行业中测定VWF浓缩物的VWF:RCo需要进行高倍手动样本稀释,这是检测不精确的主要来源。我们首次提出了一种精确且准确的方法来测定VWF:RCo,其中所有关键的移液和混合步骤均实现自动化。在赛多利斯FeliX(耶拿分析仪器公司)液体处理系统上建立了预稀释设置,并在BCS-XP分析仪(西门子公司)上采用了改良的VWF:RCo方法。在三种不同的、最常用的凝血分析仪上执行了自动化预稀释方法,并与经验丰富的操作人员进行的手动预稀释进行了比较。对比样本检测显示出相似的检测精密度(变异系数 = 自动化方法为5.9%,手动预稀释为3.1%),并且该方法中自动化方法与专家手动稀释之间无显著差异。虽然自动化程序未产生异常值,但手动预稀释的错误率为8.3%。总体而言,这种独立于操作人员的方案实现了标准化,并提供了一种完全自动化VWF活性检测的有效方法,同时保持了专家分析人员的精密度和准确性。关键特性 • 针对各种性质的血管性血友病因子浓缩物的自动化预稀释设置。 • 液体处理系统(赛多利斯FeliX)与凝血分析仪(BCS-XP)的组合。 • 简化了方法向其他实验室的转移。 • 需要对赛多利斯FeliX和BCS-XP进行基础培训。图形概述 表面带负电荷(---)的血小板(黄色椭圆体)用甲醛处理,这会使细胞表面部分变性,从而稳定血小板以用作检测试剂。然后使稳定化的血小板(深黄色边框的黄色椭圆体)与瑞斯托霉素A(所示化学结构;黑点)接触,瑞斯托霉素A与血小板表面结合并促进VWF(绿色圆圈)的结合。这些图表展示了通过测量光透射定量测定血小板凝集的一个示例,其中随着VWF量的增加,光透射随时间增加。左下角的照片显示了用于VWF样本稀释的赛多利斯FeliX设置,右下角的照片展示了用于VWF:RCo测量的BCS-XP系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92b0/11393304/6ae416a2c880/BioProtoc-14-17-5059-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验